Kailera Therapeutics Inc. (KLRA)
NASDAQ: KLRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
KLRA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.43B
- EPS (TTM)
- -$4.16
- Dividend yield
- None
- 52-week range
- 9.76 – 28.23
- Day range
- 11.00 – 11.87
- Volume / Avg
- 553.23K / 1.08M
- Beta
- —
- Shares outstanding
- 129.85M
52-week range
KLRA stock today
Kailera Therapeutics (KLRA) closed at $11.02 on Nov 20, down 4.84% (-$0.56), versus the S&P 500's 3.70% decline. At this level, KLRA sits near the bottom of its 52-week range of $9.76 to $28.23: 61.0% below the high, set on Apr 20, 2026 and 12.9% above the low. Kailera Therapeutics has posted a net loss over the last twelve months (EPS of -$4.16), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Kailera Therapeutics
Company profileKailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Ronald C. Renaud Jr., M.B.A.
- Headquarters
- Waltham, MA
- Employees
- 145
- IPO year
- 2026
- Website
- kailera.com
Analyst forecast
ForecastConsensus (7 analysts)
strong_buy
Avg. price target
$43.00+290.20%
- Strong buy 1
- Buy 6
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 11, 2026
- EPS actual vs est.
- $-0.74 vs $-1.55
- Surprise
- +52.26%
KLRA news
All KLRA news- Canaccord Genuity Initiates Coverage of Kailera Therapeutics with Buy RatingNasdaqKLRA, BIO.B
- Kailera Therapeutics reports Q3 resultsSeeking Alpha
- Kailera Reports Third Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswire
- Kailera Therapeutics to Participate in November Investor ConferencesGlobeNewswire
- 3 Under-the-Radar Stocks to Buy and Hold for a DecadeNasdaqMDGL, LLY, NVO, AXSM
Kailera Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SRPTSarepta Therapeutics Inc. | 13.33 | -5.93% | $1.43B | vs KLRA |
| DMRADamora Therapeutics Inc. | 23.22 | -4.44% | $1.44B | vs KLRA |
| ADRXADARx Pharmaceuticals Inc. | 12.79 | -9.68% | $1.42B | vs KLRA |
| NRIXNurix Therapeutics Inc. | 12.85 | -5.55% | $1.40B | vs KLRA |
| TYRATyra Biosciences Inc. | 20.12 | +1.98% | $1.39B | vs KLRA |
| ANABAnaptysBio Inc. | 46.63 | -1.62% | $1.39B | vs KLRA |
| RAPPRapport Therapeutics Inc. | 23.16 | -1.82% | $1.37B | vs KLRA |
| QUREuniQure N.V. | 19.35 | -4.35% | $1.36B | vs KLRA |
Indexes, lists and sector
Kailera Therapeutics stock FAQ
What is Kailera Therapeutics's stock price today?
KLRA last traded at $11.02 as of Nov 20, 4:00 PM EST, down 4.84% on the day. Prices are delayed at least 15 minutes.
Who is Kailera Therapeutics's CEO?
Mr. Ronald C. Renaud Jr., M.B.A. is the chief executive officer of Kailera Therapeutics Inc., which has about 145 employees.
What is the KLRA 52-week high?
The 52-week high for KLRA is $28.23 and the 52-week low is $9.76. The stock is currently 61.0% below its high.